MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2025)

MapLight Therapeutics' (MPLT) quarterly Income from Continuing Operations came in at 80907000.0 in Q4 2025, down 269.81% year-on-year from 47645644.69 in Q4 2024, and down 170.15% quarter-over-quarter from 29949000.0 in Q3 2025.

MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2025) Analysis & Trends

MapLight Therapeutics has disclosed Income from Continuing Operations across 2 years of filings, most recently posting 80907000.0 for Q4 2025.

  • Income from Continuing Operations for Q4 2025 came in at 80907000.0, down 269.81% year-over-year; the trailing twelve-month figure through Dec 2025 was 152547000.0 (changed N/A YoY), and the FY2025 annual result was 163565000.0, down 108.52% from the prior year.
  • Income from Continuing Operations came in at 80907000.0 for Q4 2025 at MapLight Therapeutics, down from 29949000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 19813000.0 in Q3 2024 to a low of 80907000.0 in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -2.97 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 30.80 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.40 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 MapLight Therapeutics 248.88 Mn 248.88 Mn - -80.91 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -80.91 Mn
Sep 30, 2025 -29.95 Mn
Dec 31, 2024 -21.88 Mn
Sep 30, 2024 -19.81 Mn